OncoGenex Pharma (NASDAQ: OGXI) announced results from the randomized, controlled Phase 2 Borealis-1 trial evaluating low and high dose (600mg ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE